Remo Christen – Early paid access in Switzerland – Switzerland, wonderland??
From MAP - Market Access Podcast · 34:11
Show by Dr. Stefan Walzer
In this Podcast episode, Dr. Stefan Walzer is discussing the specifics of the Swiss market access & reimbursement specifics including the famous article 71, which allows an early paid access. Who else could better speak about the Swiss system with him than Remo Christen? Remo is working since > 20 years in the Swiss market access environment in a leading role at Roche’s Swiss affiliate. In this episode, listeners will learn the specifics of the Swiss culture, the reimbursement process also in comparison to the German AMNOG and why Switzerland is attractive for drug launches.Subscribe with your favorite podcasting platform. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de
More episodes of MAP - Market Access Podcast
More episodes
- How Will the EU JCA Reshape National HTA Across Europe, Dr. Oriol Solà-Morales?
- How Can HEOR Teams Build Trust in AI-Generated Models, Haidong Feng?
- Can US GLOBE and GUARD Models Really Lower Drug Prices, Brittany La Couture?
- What Will It Take to Keep Biotech Growing in Europe, Rainer Westermann?
- How Do You Build a High-Performing Team in Pharma, Dr. Maurice Kléber?
- Dr. Mathias Flume - AMNOG will change in 2022, but how?
- Prof. Dr. Wagschal - What can we expect from the upcoming elections in Germany?
- Prof. Dr. David Matusiewicz & Dr. Anne Sophie Geier - 1 year DIGAs. Is the "fast track process" for digital health applications successful?
- Bibiane Schulte-Bosse - How to fight well in AMNOG negotiations.
- Prof. Peter Zweifel & Door Vonk - Digital innovation - from theory into practice!
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.